Effects of Endocytosis on the Receptor Targeting Mechanism of ADC Drugs
ADC is a complex that conjugates cytotoxic small molecule drugs to monoclonal antibodies through a rationally constructed linker, which can selectively deliver effective cytotoxic drugs into tumors. Currently, the FDA has approved 14 ADC drugs for marketing, and hundreds more are in clinical trials.In addition to overexpression in tumors, another important factor in the selection of ADC drug targets is the efficiency of endocytosis, which is necessary for drug release activity.
